Related Experiment Videos
Structure-function interrelation and clinical effect of atrial natriuretic peptide (ANP)
Chinese Medical Journal
|April 1, 1995
Summary
Synthesized Atriopeptin III analogues show potent diuretic and hypotensive effects. [D-Ala-5, D-Arg-23] AP III demonstrated significantly enhanced diuretic activity, offering potential for treating hypertension.
Area of Science:
- Cardiovascular Pharmacology
- Medicinal Chemistry
- Nephrology
Background:
- Atriopeptin III (AP III) is a natriuretic peptide with known diuretic and hypotensive properties.
- Understanding structure-activity relationships is crucial for developing more effective therapeutic agents.
Purpose of the Study:
- To synthesize and evaluate the diuretic and hypotensive activities of Atriopeptin III (AP III) and its novel analogues.
- To identify analogues with improved potency and efficacy compared to the parent compound.
Main Methods:
- Solid-phase synthesis was employed to create AP III and six analogues.
- Diuretic and hypotensive activities were quantitatively assessed in experimental models.
Main Results:
- Analogue [D-Ala-5, D-Arg-23] AP III exhibited approximately 10-fold greater diuretic potency than AP III, with a 50% increase in hypotensive activity.
- Analogue des [Ser-15Gly-16Leu-17Gly-18Asn-20Ser-21] AP III retained 60% of AP III's hypotensive activity while showing 15% of its diuretic potency.
- [D-Ala-5, D-Agr-23] AP III showed promising results in treating hypertensive syndromes of pregnancy.
Conclusions:
- Specific modifications to the AP III structure can significantly enhance diuretic activity while modulating hypotensive effects.
- The analogue [D-Ala-5, D-Arg-23] AP III represents a promising candidate for further investigation in managing hypertension, particularly in pregnancy.